Marker Therapeutics (MRKR) Expected to Release Quarterly Earnings on Thursday

Marker Therapeutics (NASDAQ:MRKR) is expected to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Marker Therapeutics to announce earnings of ($0.25) per share and revenue of $0.6820 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%.The business had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.78 million. On average, analysts expect Marker Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Marker Therapeutics Stock Performance

MRKR opened at $1.15 on Thursday. Marker Therapeutics has a 52-week low of $0.81 and a 52-week high of $2.46. The stock has a market capitalization of $19.09 million, a PE ratio of -1.88 and a beta of 1.50. The stock’s 50 day moving average price is $1.37 and its 200-day moving average price is $1.46.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on MRKR shares. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a report on Wednesday, May 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Marker Therapeutics in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Marker Therapeutics currently has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Investors Weigh In On Marker Therapeutics

Several hedge funds have recently made changes to their positions in MRKR. Jane Street Group LLC purchased a new stake in Marker Therapeutics in the second quarter worth $33,000. Virtu Financial LLC purchased a new position in Marker Therapeutics during the third quarter valued at $25,000. Two Sigma Investments LP purchased a new position in Marker Therapeutics during the third quarter valued at $33,000. XTX Topco Ltd lifted its position in Marker Therapeutics by 166.6% during the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after buying an additional 36,269 shares during the period. Finally, LPL Financial LLC boosted its holdings in shares of Marker Therapeutics by 41.7% during the 4th quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after buying an additional 24,500 shares in the last quarter. 22.39% of the stock is currently owned by institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.